Spots Global Cancer Trial Database for advanced clear cell renal cell carcinoma
Every month we try and update this database with for advanced clear cell renal cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | NCT05122546 | Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re... | Cabozantinib S-... Clostridium but... Nivolumab | 18 Years - | City of Hope Medical Center | |
| Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | NCT03260504 | Advanced Clear ... Stage III Renal... Stage IV Renal ... Metastatic Clea... | Aldesleukin Pembrolizumab | 18 Years - | University of Washington | |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | NCT05122546 | Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re... | Cabozantinib S-... Clostridium but... Nivolumab | 18 Years - | City of Hope Medical Center | |
| CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer | NCT05122546 | Advanced Clear ... Advanced Papill... Advanced Renal ... Advanced Sarcom... Metastatic Clea... Metastatic Papi... Metastatic Rena... Metastatic Sarc... Stage III Renal... Stage IV Renal ... Unresectable Cl... Unresectable Re... | Cabozantinib S-... Clostridium but... Nivolumab | 18 Years - | City of Hope Medical Center | |
| Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | NCT03260504 | Advanced Clear ... Stage III Renal... Stage IV Renal ... Metastatic Clea... | Aldesleukin Pembrolizumab | 18 Years - | University of Washington | |
| Vandetanib to Treat Advanced Kidney Cancer | NCT01372813 | Advanced Clear ... | vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | NCT05361720 | Advanced Clear ... Metastatic Clea... Stage III Renal... Stage IV Renal ... | Cabozantinib Ipilimumab Nivolumab | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer | NCT05012371 | Advanced Clear ... Metastatic Clea... Stage III Renal... Stage IV Renal ... | Cabozantinib Everolimus Lenvatinib Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma | NCT06049030 | Renal Cell Carc... | HS-10516 | 18 Years - 75 Years | Jiangsu Hansoh Pharmaceutical Co., Ltd. | |
| Avelumab, Palbociclib and Axitinib in Advanced RCC | NCT05176288 | Advanced Clear ... | Axitinib Palbociclib Avelumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Clinical Study of 6MW3211 in Patients With Renal Cancer | NCT05440045 | Advanced Clear ... | 6MW3211 | 18 Years - 75 Years | Mabwell (Shanghai) Bioscience Co., Ltd. | |
| Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer | NCT03260504 | Advanced Clear ... Stage III Renal... Stage IV Renal ... Metastatic Clea... | Aldesleukin Pembrolizumab | 18 Years - | University of Washington | |
| Vandetanib to Treat Advanced Kidney Cancer | NCT01372813 | Advanced Clear ... | vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer | NCT04904302 | Advanced Clear ... Metastatic Clea... Stage IV Renal ... | Nivolumab Quality-of-Life... Questionnaire A... Sitravatinib | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
